Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Kite Pharma, Inc. | d875574dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 17, 2015
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-36508 | 27-1524986 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) | ||
| 2225 Colorado Avenue Santa Monica, California |
90404 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (310) 824-9999
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry into a Material Definitive Agreement. |
On February 17, 2015, Kite Pharma, Inc. (“Kite”) entered into a Lease Agreement (the “Lease”) with 2355 Utah Industrial Capital, LLC, for the lease of approximately 43,500 square feet in El Segundo, which is adjacent to Los Angeles International Airport. The Lease has a 10 year and seven month term commencing on January 1, 2016. Upon certain conditions, Kite has two options to extend the lease, each for an additional five years. Kite paid $124,183.05 upon execution of the Lease and is required to remit base rent of $124,183.05 per month, or $2.85 per square foot, which will increase at a rate of 3% per year. The monthly installments will be abated for the months of February 2016, January and February 2017, January 2018, January 2019, January 2020 and January 2021. Kite also has an option to expand the lease for an extra 17,000 square feet at the same rent per square foot as the base premises, which option must be exercised prior to July 1, 2017.
Kite announced the Lease in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibit is filed as part of this Current Report:
| 99.1 | Press Release of Kite issued February 19, 2015. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 19, 2015 | KITE PHARMA, INC. (Registrant) | |||||
| By: | /s/ Cynthia M. Butitta | |||||
| Name: | Cynthia M. Butitta | |||||
| Title: | Chief Financial Officer and Chief Operating Officer | |||||